COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015 - 2022

  • ID: 3046126
  • Report
  • Region: Global
  • 158 pages
  • Allied Analytics LLP
1 of 6
COPD and Asthma Devices Market is Expected to Reach $34.3 Billion, Global, by 2020

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Novartis AG
  • MORE
Asthma is a chronic respiratory disease blocking the airways of the lungs because of the inflammation, mucus production, tighten of muscles. The general symptoms are coughing, wheezing, shortness of breath and/or chest tightness and majorly these symptoms are closely related to the physical activity. There are different types of asthma, exercise-induced bronchoconstriction(EIB), allergic asthma, occupational asthma, childhood asthma. Chronic Obstructive Pulmonary Disease (COPD) is also respiratory disease which causes obstructions and difficulty in breathing, the primary cause of COPD is tobacco smoking and chemical flumes, dust, air pollution are minor causes of the disease. Major symptoms are long lasting cough, mucus that comes out along with cough, shortness of breath.

The world COPD and asthma drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Increase in prevalence of asthma and COPD, increase in world ageing population, technological advancement in the treatment of asthma and COPD, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market. Stringent government regulatory requirement for the approval of COPD and asthma drug, patent expiry of branded hamper the market growth.

The world asthma and COPD drugs market is segmented based on disease and medication class and geography. On the basis of disease, the market is segmented into COPD and asthma. Based on medication class, the world asthma and COPD drug market is segmented into combination products, short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids (ICS), leukotriene antagonists (LTA), anticholinergics and others. And geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits:

The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.
Key market segments
The world COPD and asthma drug market is segmented by medication class, disease and geography.

MARKET BY DISEASES

COPD
Asthma

MARKET BY MEDICATION CLASS

Combination Products
Seretide/Advair
Symbicort
Relvar/Breo Ellipta
Flutiform
Dulera
Others
Leukotriene Antagonists (LTA)
Singulair
Others
Inhaled Corticosteroids (ICS)
Qvar
Pulmicort
Aerospan
Flovent
Others
Anticholinergics
Spiriva
Others
Short Acting Beta Agonists(SABA)
ProAir
Ventolin
Others
Long Acting Beta Agonists (LABA)
Others

MARKET BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Novartis AG
  • MORE
CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Reseaarch methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 Porters five forces analysis

3.3.1 Bargaining power of buyers (High)
3.3.2 Bargaining power of suppliers (Low to Moderate)
3.3.3 Threat of new entrants (Low)
3.3.4 Threat of substitutes (High)
3.3.5 Intense competitive rivalry

3.4 Market dynamics

3.4.1 Drivers

3.4.1.1 Increasi in number of asthmatic and COPD patients worldwide
3.4.1.2 Increase in world ageing population
3.4.1.3 Technological advancement in the treatment of asthma and COPD drugs
3.4.1.4 Initiatives taken by various government associations to raise awareness about daignosis and management of asthma and COPD
3.4.1.5 Increasing number of products in the pipeline

3.4.2 Restraints

3.4.2.1 Stringent regulatory requirements for the approval and commercialization of asthma and COPD drugs
3.4.2.2 Asthma and COPD drugs show side effects
3.4.2.3 Asthma and COPD drug approval process is expensive and time-consuming
3.4.2.4 Patent expiry of asthma and COPD drugs

3.4.3 Opportunities

3.4.3.1 Inrtoduction of generic drugs of asthma and COPD drugs

3.5 Market share analysis, 2015

CHAPTER 4 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE

4.1 Overview
4.2 Asthma

4.2.1 Global prevalence
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 COPD

4.3.1 Global prevalence
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

CHAPTER 5 GLOBALASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS

5.1 Overview
5.2 Combination Drugs

5.2.1 Market size and forecast
5.2.2 Seretide/Advair
5.2.3 Symbicort
5.2.4 Relvar/Breo Ellipta
5.2.5 Flutiform
5.2.6 Dulera

5.3 Leukotriene antagonists (LTA)

5.3.1 Market size and forecast
5.3.2 Singulair

5.4 Inhaled corticosteroids (ICS)

5.4.1 Market size and forecast
5.4.2 Qvar
5.4.3 Pulmicort
5.4.4 Aerospan
5.4.5 Flovent

5.5 Anticholinergics

5.5.1 Market size and forecast
5.5.2 Spiriva

5.6 Short acting beta agonists (SABA)

5.6.1 Market size and forecast
5.6.2 ProAir
5.6.3 Ventolin

5.7 Long acting beta agonists (LABA)

5.7.1 Market size and forecast

5.8 Others

5.8.1 Market size and forecast

CHAPTER 6 GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 U.S.: market size and forecast
6.2.5 Canada market size and forecast
6.2.6 Mexico: market size and forecast

6.3 Europe

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Germany: market size and forecast
6.3.4 France market size and forecast
6.3.5 UK: market size and forecast
6.3.6 Italy market size and forecast
6.3.7 Rest of Europe: market size and forecast

6.4 Asia-Pacific

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Japan: market size and forecast
6.4.5 China market size and forecast
6.4.6 India: market size and forecast
6.4.7 Rest of Asia-Pacific market size and forecast

6.5 LAMEA

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Latin America: market size and forecast
6.5.5 Middle East market size and forecast
6.5.6 Africa: market size and forecast

CHAPTER 7 GLOBALASTHMA AND COPD DRUGS PIPELINE -2015

CHAPTER 8 COMPANY PROFILES

8.1 Boehringer Ingelheim International GmbH

8.1.1 Company overview
8.1.2 Operating business segments
8.1.3 Business performance
8.1.4 Key strategic moves & developments

8.2 Merck & Co., Inc.

8.2.1 Company overview
8.2.2 Operating business segments
8.2.3 Business performance
8.2.4 Key strategic moves & developments

8.3 GlaxoSmithKline PLC.

8.3.1 Company overview
8.3.2 Operating business segments
8.3.3 Business performance
8.3.4 Key strategic moves & developments

8.4 Novartis AG

8.4.1 Company overview
8.4.2 Operating business segments
8.4.3 Business performance
8.4.4 Key strategic moves & developments

8.5 AstraZeneca

8.5.1 Company overview
8.5.2 Operating business segments
8.5.3 Business performance
8.5.4 Key strategic moves & developments

8.6 F. Hoffmann-La Roche Ltd

8.6.1 Company overview
8.6.2 Operating business segments
8.6.3 Business performance
8.6.4 Key strategic moves & developments

8.7 Teva Pharmaceutical Industries Ltd.

8.7.1 Company overview
8.7.2 Operating business segments
8.7.3 Business performance
8.7.4 Key strategic moves & developments

8.8 Vectura Group plc.

8.8.1 Company overview
8.8.2 Operating business segments
8.8.3 Business performance
8.8.4 Key strategic moves & developments

8.9 Pfizer, Inc.

8.9.1 Company overview
8.9.2 Operating business segments
8.9.3 Business performance
8.9.4 Key strategic moves & developments

8.10 Abbott Laboratories

8.10.1 Company overview
8.10.2 Operating business segments
8.10.3 Business performance
8.10.4 Key strategic moves & developments
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Novartis AG
  • MORE
According to a new report titled,"World COPD and Asthma Devices" Market the global COPD and asthma devices market would reach $34.3 billion by 2020, registering a CAGR of 4.5% during 2014 - 2020. Considering the growth and market size, Dry Powder Inhalers (DPIs) will be the most lucrative market segment of the COPD and Asthma devices (inhalers) market by 2020. Metered Dose Inhalers (MDIs) are the largest revenue generating segment currently and would maintain the stand till 2020.

The need for urgency in medication and portability of the drug delivery devices will drive the growth for COPD and Asthma devices. Despite notable advantages of the COPD and Asthma devices, some factors such as environmental concerns are likely to impede the growth of COPD and Asthma devices market. It is observed that the inhalers, particularly the MDIs, release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA), which is negatively impacting growth of the MDIs segment. Consumption pattern will shift to better alternatives, namely the DPIs. The Soft Mist Inhalers (SMIs), which are another type of inhalers, deliver a metered dosage of medication as a soft mist. Such form of drug delivery is ~65% to 80% more efficacious than its peers and will eventually display higher growth as compared to its peers.

Nebulizers, electric or battery powered machines that dispense medication as a fine mist, are ideal for home healthcare set-up for debilitated patients, geriatrics and children. Nebulizers segment thus holds about 13% of the global COPD and Asthma devices market; however, the nebulizers market is forecast to have diminishing growth through 2020 as nebulizers are rendered ineffectual, as POC or portable COPD and Asthma devices due to its larger set up.

Key findings of the study:

Drug powder inhalers (DPIs) segment will grow at a CAGR of 5.3% during the forecast period, fastest among all
The North American market would be one of the most lucrative markets, in terms of growth
The European market for COPD and asthma devices would reach$10 billion by 2020, with the CAGR of 4.8%
Within the nebulizers segment markets, compressor nebulizers would be morelucrative, growing at 7% CAGR during the forecast period and compressor nebulizers would garner 81.5% market share by 2020
Specific focus to achieve product differentiation and thus gain competitive advantage drives the development of new product variants of COPD and Asthma devices. In accordance to the afore-mentioned trend, the market has witnessed a steady stream of product launch.

Key product manufacturing companies profiled in the report include GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Philips Healthcare, 3M Health Care, Allied Healthcare Products Inc., Sunovion Pharmaceuticals Inc., GF Healthcare Products, Smith Medicals, Lincare Holdings Inc. and Baxter International.
Note: Product cover images may vary from those shown
5 of 6
  • GlaxoSmithKline (GSK)
  • Novartis AG
  • Merck & Co
  • Abbott Laboratories
  • Boehringer Ingelheim
  • AstraZeneca
  • Roche Holding AG
  • Teva Pharmaceutical Industries
  • Vectura Group
  • Pfizer
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll